It Kills That: Cramer Won’t Recommend Pfizer 7% Yield
Jim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
Find out Where To Position Dividend Aristocrats Etf In Portfolio to optimize diversification, risk, and income potential within a blended strategy.
18,597 articlesJim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
Apple accelerates its cash-return program with a fresh buyback authorization and a dividend bump, underscoring a disc...
Two stalwarts of the insurance world compete for a spot in a 2026 portfolio. This article breaks down Lincoln Nationa...
Unlock a practical, investor-friendly view of arbor realty (abr) earnings. Learn what drives ABR earnings, how to int...
Buffett’s longest-running wager sits in plain sight: a simple, legendary drink that built a fortress around its brand...
A landmark portfolio reshuffle puts Alphabet ahead of Berkshire's long-time Coca-Cola cornerstone. This analysis expl...
Gold has rallied about 73% over the past year as inflation jitters fade and risk-off trades surge. This report shows ...
Silver prices have swung wildly and the SLV ETF has fallen in recent months. This guide breaks down what’s driving th...
While Nvidia grabs the spotlight with GPUs, Broadcom quietly powers AI at scale with custom accelerators. This articl...
As traditional bonds yield less in a volatile rate environment, retirees are turning to covered-call ETFs such as JEP...
A low-cost rival ETF now mirrors the S&P 500 with identical holdings, challenging VOO on fees. The move spotlights ho...
Constellation Energy stock tumbling has sparked questions for investors. This deep dive explains the macro and compan...